These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 31126191)

  • 1. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
    Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
    Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
    Xu W; Yang Y; Hu Z; Head M; Mangold KA; Sullivan M; Wang E; Saha P; Gulukota K; Helseth DL; Guise T; Prabhkar BS; Kaul K; Schreiber H; Seth P
    Hum Gene Ther; 2020 Aug; 31(15-16):863-880. PubMed ID: 32394753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model.
    Zhao H; Wang H; Kong F; Xu W; Wang T; Xiao F; Wang L; Huang D; Seth P; Yang Y; Wang H
    Hum Gene Ther; 2019 Feb; 30(2):197-210. PubMed ID: 30032645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.
    Hu Z; Robbins JS; Pister A; Zafar MB; Zhang ZW; Gupta J; Lee KJ; Newman K; Yun CO; Guise T; Seth P
    Cancer Gene Ther; 2010 Apr; 17(4):235-43. PubMed ID: 19798122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
    Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
    Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.
    Dai S; Lv Y; Xu W; Yang Y; Liu C; Dong X; Zhang H; Prabhakar BS; Maker AV; Seth P; Wang H
    Cancer Gene Ther; 2020 Dec; 27(12):923-933. PubMed ID: 32307442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
    Seth P; Wang ZG; Pister A; Zafar MB; Kim S; Guise T; Wakefield L
    Hum Gene Ther; 2006 Nov; 17(11):1152-60. PubMed ID: 17032151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
    Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
    Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model.
    Rong Y; Ning Y; Zhu J; Feng P; Zhu W; Zhao X; Xiong Z; Ruan C; Jin J; Wang H; Cai T; Zhang S; Yang Y
    Mol Biomed; 2024 Sep; 5(1):39. PubMed ID: 39306655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
    Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
    Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model.
    Shin SC; Vickman RE; Filimon B; Yang Y; Hu Z; Mangold KA; Prabhakar BS; Schreiber H; Xu W
    Cancer Gene Ther; 2024 Apr; 31(4):574-585. PubMed ID: 38267626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
    Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
    Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.
    Hu Z; Zhang Z; Guise T; Seth P
    Hum Gene Ther; 2010 Nov; 21(11):1623-9. PubMed ID: 20712434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
    Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
    Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.